Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebocontrolled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

1. Vansteenkiste, J.
2. Zielinski, M.
3. Linder, A.
4. Dahabre, J.
5. Esteban, E.
6. Malinowski, W.
7. Jassem, J.
8. Passlick, B.
9. Lopez-Brea, M.
10. Vanakesa, T.